Downregulation of SIRT6 leads to an increase in doxorubicin-induced death of hepatocellular carcinoma cells by inducing FOXO3 to translocate into the nucleus and bind its target genes P27 and Bim [33]. The gene discussed is BCL2L11; the disease is hepatocellular carcinoma.